Profile data is unavailable for this security.
About the company
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
- Revenue in CAD (TTM)0.00
- Net income in CAD-8.36m
- Incorporated2019
- Employees--
- LocationRakovina Therapeutics Inc105 - 1008 Beach AvenueVancouver V6E 1T7CanadaCAN
- Phone+1 (604) 619-0225
- Fax+1 (604) 980-6264
- Websitehttps://www.rakovinatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 218.92k | -2.96m | 1.99m | 7.00 | -- | -- | -- | 9.07 | -0.024 | -0.024 | 0.0018 | -0.1276 | 0.1658 | -- | 0.3197 | -- | -224.12 | -143.75 | -- | -1,382.22 | -- | -- | -1,352.14 | -2,076.82 | -- | -3.50 | -- | -- | -87.86 | -12.79 | 30.58 | -- | 16.92 | -- |
| Rakovina Therapeutics Inc | 0.00 | -8.36m | 3.07m | -- | -- | 1.62 | -- | -- | -0.5705 | -0.5705 | 0.00 | 0.0893 | 0.00 | -- | -- | -- | -158.14 | -- | -221.29 | -- | -- | -- | -- | -- | -- | -21.46 | 0.579 | -- | -- | -- | -55.86 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -2.66m | 3.39m | 3.00 | -- | 0.9389 | -- | -- | -0.6465 | -0.6465 | 0.00 | 0.5179 | 0.00 | -- | -- | -- | -58.35 | -39.11 | -94.63 | -43.59 | -- | -- | -- | -- | -- | -- | 0.0291 | -- | -- | -- | -53.53 | -- | 48.96 | -- |
